ArticleAvicenna journal of phytomedicine
Therapeutic effect of frankincense in a rat model of Alzheimer's disease.
Article in Avicenna journal of phytomedicine. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 30 citations in OpenAlex.
- The clinical efficacy of Olibanum gum chewing in patients with Mild-to-Moderate Alzheimer disease: A randomized Parallel-Design controlled trial.Neuropsychopharmacology reports · 2024Trial
- Assessment of Anti-Alzheimer Pursuit of Jambolan Fruit Extract and/or Choline against AlClToxics · 2023Article
- Neuroprotective and anti-neuroinflammatory activity of frankincense in bile duct ligaion-induced hepatic encephalopathy.Iranian journal of basic medical sciences · 2023Article
- The anti-Alzheimer potential ofRSC advances · 2022Article
- Potential therapeutic effects of boswellic acids/Boswellia serrata extract in the prevention and therapy of type 2 diabetes and Alzheimer's disease.Naunyn-Schmiedeberg's archives of pharmacology · 2021Review
- GenusIranian journal of basic medical sciences · 2020Review
- Enhanced Bioavailability of Boswellic Acid byFrontiers in pharmacology · 2020Article
- Protein Targets of Frankincense: A Reverse Docking Analysis of Terpenoids fromMedicines (Basel, Switzerland) · 2018Article
- The effects of pre-treatment with olibanum and its constituent, boswellic acid on synaptic plasticity impairments induced by lipopolysaccharide in rats.Avicenna journal of phytomedicineArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveFrankincense improves memory in different models of learning. However, its influence on models of Alzheimer's disease (AD) has not been studied widely. In the present study, the therapeutic effect of frankincense was evaluated in a model of AD induced by i.c.v administration of streptozotocin. MATERIALS AND
methodsUnder stereotaxic surgery, two guide cannulas were implanted in the lateral ventricles of adult male Wistar rats weighing 230-270 g. One group received streptozotocin (1.5 mg/kg/2μl/side) bilaterally on the first and third day of surgery. Another group received artificial cerebro-spinal fluid. Fourteen days after surgery, learning was evaluated using the passive avoidance paradigm. Four other groups of animals received frankincense (50 mg/kg) or its solvent after establishment of AD for 21 or 42 consecutive days, and then, memory retrieval was assessed.
resultsStreptozotocin increased the number of stimulations required for induction of short-term memory and decreased step-through latency on the test day, significantly (p<0.05). Chronic injection of the aqueous extract of frankincense for 21 days did not affect learning parameters, but injection of it for 42 days, significantly increased step-through latency (p<0.05), decreased the number of step-through into the dark compartment (p<0.01) and decreased the time spent in the dark compartment (p<0.05).
conclusionThe results indicate that chronic administration of frankincense has the potential to improve dementia type of AD induced by i.c.v injection of streptozotocin in a time-dependent manner.
Indexed as
Identifiers
27516988PMC4967843W2278533645What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.